ADMA Biologics, Inc. Share Price

Equities

ADMA

US0008991046

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
6.55 USD +1.71% Intraday chart for ADMA Biologics, Inc. +4.47% +44.91%
Sales 2024 * 334M 27.83B Sales 2025 * 390M 32.52B Capitalization 1.52B 127B
Net income 2024 * 67M 5.59B Net income 2025 * 114M 9.51B EV / Sales 2024 * 4.55 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.89 x
P/E ratio 2024 *
22.2 x
P/E ratio 2025 *
13.1 x
Employees 624
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.47%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.71%
1 week+4.47%
Current month-0.76%
1 month-2.82%
3 months+28.68%
6 months+97.89%
Current year+44.91%
More quotes
1 week
6.19
Extreme 6.19
6.63
1 month
5.90
Extreme 5.895
6.66
Current year
4.37
Extreme 4.37
6.76
1 year
3.06
Extreme 3.06
6.76
3 years
1.01
Extreme 1.01
6.76
5 years
1.01
Extreme 1.01
6.76
10 years
1.01
Extreme 1.01
14.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 02/06/02
Compliance Officer 37 01/11/01
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 73 24/12/24
Director/Board Member 51 01/12/01
Chairman 60 01/07/01
More insiders
Date Price Change Volume
26/24/26 6.55 +1.71% 1,565,517
25/24/25 6.44 -0.31% 1,531,854
24/24/24 6.46 -1.22% 1,716,472
23/24/23 6.54 +5.48% 2,752,319
22/24/22 6.2 -1.12% 2,301,644

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
6.55 USD
Average target price
8.375 USD
Spread / Average Target
+27.86%
Consensus